CompletedNCT00719706
Acetyl-L-carnitine, alpha-lipoic acid or placebo for bipolar depression
About this title
The Use of a Mitochondrial Enhancement Treatment in Bipolar Disorder
Read the official source — NCT00719706Medication studyAges 18–65United StatesBipolarity
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- BelmontSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateAugust 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 40
- Sponsor
- Mclean Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00719706
- Official title
Show the full official title
The Use of a Mitochondrial Enhancement Treatment in Bipolar Disorder: A Randomized, Placebo-Controlled Trial of Acetyl-L-Carnitine and Alpha-Lipoic Acid for the Treatment of Bipolar Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Belmont
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Mclean Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including acetyl-l-carnitine PLUS alpha-lipoic acide and Placebo.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
